Fate Therapeutics Licenses Stem-Cell Modulators for Bone Regeneration from UCLA | GenomeWeb

Stem cell therapeutics company Fate Therapeutics said today that it has acquired from the University of California, Los Angeles, exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation.

With the deal, UCLA becomes at least the eighth university or research institution from which Fate has licensed IP to bolster its portfolio of stem-cell modulators — small molecules and biologics to modulate cells for therapeutic purposes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.